Identification
- Summary
Ferrous fumarate is a medication used to treat iron-deficiency anemia.
- Brand Names
- Aurovela Fe, Concept Ob, Hailey Fe 1.5/30 28 Day, Hematogen, Microgestin Fe 1/20 28 Day, Pregvit, Tandem, Tandem Plus, Tarina 24 Fe 1/20 28 Day
- Generic Name
- Ferrous fumarate
- DrugBank Accession Number
- DB14491
- Background
Used in treatment of iron deficiency anemia.
- Type
- Small Molecule
- Groups
- Approved
- Structure
Structure for Ferrous fumarate (DB14491)
- Weight
- Average: 169.901
Monoisotopic: 169.930250685 - Chemical Formula
- C4H2FeO4
- Synonyms
- Ferrous fumarate
- Iron(2+) fumarate
Pharmacology
- Indication
Used in preventing and treating iron-deficiency anemia.
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Associated Conditions
Indication Type Indication Combined Product Details Approval Level Age Group Patient Characteristics Dose Form Used in combination to prevent Folic acid deficiency Combination Product in combination with: Folic acid (DB00158) ••• ••• ••••••••••••• ••••••••• Used in combination to prevent Iron deficiency Combination Product in combination with: Folic acid (DB00158) ••• ••• ••••••••••••• ••••••••• Treatment of Iron deficiency anemia •••••••••••• Prevention of Iron deficiency anemia •••••••••••• - Associated Therapies
- Contraindications & Blackbox Warnings
Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API- Pharmacodynamics
The major activity of supplemental iron is in the prevention and treatment of iron deficiency anemia. Iron has putative immune-enhancing, anticarcinogenic and cognition-enhancing activities.
- Mechanism of action
Iron is necessary for the production of hemoglobin. Iron-deficiency can lead to decreased production of hemoglobin and a microcytic, hypochromic anemia.
Target Actions Organism UTransferrin receptor protein 1 Not Available Humans UEgl nine homolog 1 Not Available Humans UHistone deacetylase 8 Not Available Humans UAlpha-hemoglobin-stabilizing protein Not Available Humans UHemoglobin subunit alpha Not Available Humans UFrataxin, mitochondrial Not Available Humans UFerritin heavy chain Not Available Humans UFlap endonuclease 1 Not Available Humans UEndonuclease 8-like 1 Not Available Humans UEndonuclease 8-like 2 Not Available Humans UDNA polymerase beta Not Available Humans UCeruloplasmin Not Available Humans USerotransferrin Not Available Humans - Absorption
The efficiency of absorption depends on the salt form, the amount administered, the dosing regimen and the size of iron stores. Subjects with normal iron stores absorb 10% to 35% of an iron dose. Those who are iron deficient may absorb up to 95% of an iron dose.
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Acute iron overdosage can be divided into four stages. In the first stage, which occurs up to six hours after ingestion, the principal symptoms are vomiting and diarrhea. Other symptoms include hypotension, tachycardia and CNS depression ranging from lethargy to coma. The second phase may occur at 6-24 hours after ingestion and is characterized by a temporary remission. In the third phase, gastrointestinal symptoms recur accompanied by shock, metabolic acidosis, coma, hepatic necrosis and jaundice, hypoglycemia, renal failure and pulmonary edema. The fourth phase may occur several weeks after ingestion and is characterized by gastrointestinal obstruction and liver damage. In a young child, 75 milligrams per kilogram is considered extremely dangerous. A dose of 30 milligrams per kilogram can lead to symptoms of toxicity. Estimates of a lethal dosage range from 180 milligrams per kilogram and upwards. A peak serum iron concentration of five micrograms or more per ml is associated with moderate to severe poisoning in many.
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs Browse all" title="About SNP Mediated Effects/ADRs" id="snp-actions-info" class="drug-info-popup" href="javascript:void(0);">
- Not Available
Interactions
- Drug Interactions Learn More" title="About Drug Interactions" id="structured-interactions-info" class="drug-info-popup" href="javascript:void(0);">
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareAlendronic acid Ferrous fumarate can cause a decrease in the absorption of Alendronic acid resulting in a reduced serum concentration and potentially a decrease in efficacy. Almasilate Almasilate can cause a decrease in the absorption of Ferrous fumarate resulting in a reduced serum concentration and potentially a decrease in efficacy. Aluminium phosphate Aluminium phosphate can cause a decrease in the absorption of Ferrous fumarate resulting in a reduced serum concentration and potentially a decrease in efficacy. Aluminum hydroxide Aluminum hydroxide can cause a decrease in the absorption of Ferrous fumarate resulting in a reduced serum concentration and potentially a decrease in efficacy. Asenapine Asenapine can cause a decrease in the absorption of Ferrous fumarate resulting in a reduced serum concentration and potentially a decrease in efficacy. - Food Interactions
- Avoid milk and dairy products. Take ferrous fumarate at least 2 hours before or after milk.
- Limit caffeine intake. Food and beverages containing caffeine may reduce iron absorption.
- Take at least 2 hours before or after calcium supplements.
- Take separate from antacids. Take ferrous fumarate at least 2 hours before or after antacids.
- Take with food. This reduces gastric irritation.
- Take with foods containing vitamin C. Foods rich in vitamin C increase the absorption of iron.
Products
Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.- Active Moieties
Name Kind UNII CAS InChI Key Iron unknown E1UOL152H7 7439-89-6 XEEYBQQBJWHFJM-UHFFFAOYSA-N Ferrous cation ionic GW89581OWR 15438-31-0 CWYNVVGOOAEACU-UHFFFAOYSA-N - Product Images
- Over the Counter Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Region Image DYNA FERROUS FUMARATE TABLET Tablet Oral DYNAPHARM (M) SDN BHD 2020-09-08 Not applicable Malaysia 
FEFUR TABLET (FILM-COATED) 100MG Tablet, film coated Oral Hovid Berhad 2020-09-08 Not applicable Malaysia Ferion Tab Tablet 65 mg / tab Oral Pharmetics (2011) Inc. 1981-12-31 2000-08-21 Canada 
Ferrocite Tablet, film coated 106 mg/1 Oral Breckenridge Pharmaceutical, Inc. 2003-07-01 2011-12-31 US 
FERROMAX TABLET 200MG Tablet Oral ZONTRON PHARMACEUTICALS SDN. BHD. 2020-09-08 Not applicable Malaysia - Mixture Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Region Image 24 Multivitamins + Minerals Ferrous fumarate (15 mg) + Ascorbic acid (150 mg) + Beta carotene (10000 unit) + Biotin (25 mcg) + Calcium (130 mg) + Cholecalciferol (400 unit) + Choline bitartrate (25 mg) + Chromium (20 mcg) + Copper (1 mg) + Cyanocobalamin (25 mcg) + Folic acid (.8 mg) + Inositol (25 mg) + Magnesium (65 mg) + Manganese (2 mg) + Molybdenum (20 mcg) + Niacin (25 mg) + Calcium pantothenate (25 mg) + Potassium (15 mg) + Potassium Iodide (.1 mg) + Pyridoxine hydrochloride (25 mg) + Racemethionine (25 mg) + Riboflavin (25 mg) + Selenium (20 mcg) + Thiamine hydrochloride (25 mg) + Vanadium (20 mcg) + Vitamin A palmitate (5000 unit) + Vitamin E (50 unit) + Zinc (10 mg) Tablet Oral Stanley Pharmaceuticals, A Division Of Vita Health Products Inc. 1997-04-30 2002-07-31 Canada Appedrine Ferrous fumarate (3.33 mg) + Benzocaine (3 mg) + Nicotinamide (3.33 mg) + Riboflavin (.4 mg) + Sodium ascorbate (10 mg) + Thiamine hydrochloride (.33 mg) + Vitamin A acetate (1333 unit) + Vitamin D (133 unit) Tablet Oral Chattem, Inc. 1975-12-31 2004-07-08 Canada Aurovela 24 Fe Ferrous fumarate (75 mg/1) + Ethinylestradiol (20 ug/1) + Norethisterone acetate (1 mg/1) Kit; Tablet Oral Aurobindo Pharma Limited 2017-06-15 Not applicable US Avon Vitadvance Multi-kids Complete Ferrous fumarate (4 mg) + Ascorbic acid (100 mg) + Beta carotene (2500 unit) + Biotin (60 mcg) + Calcium (125 mg) + Cholecalciferol (400 unit) + Cupric oxide (1 mg) + Cyanocobalamin (6 mcg) + Folic acid (.4 mg) + Nicotinamide (20 mg) + Calcium pantothenate (10 mg) + Potassium Iodide (.075 mg) + Pyridoxine hydrochloride (2 mg) + Riboflavin (1.7 mg) + Thiamine mononitrate (1.5 mg) + Vitamin A palmitate (2500 unit) + alpha-Tocopherol succinate (20 unit) Tablet Oral Avon Products, Inc. 1994-12-31 2005-07-29 Canada B Stress C + Iron & Vite Ferrous fumarate (27 mg) + Ascorbic acid (600 mg) + Cyanocobalamin (12 mcg) + Folic acid (.4 mg) + Nicotinamide (100 mg) + Calcium pantothenate (20 mg) + Pyridoxine hydrochloride (25 mg) + Riboflavin (15 mg) + Thiamine mononitrate (15 mg) + alpha-Tocopherol acetate (30 unit) Tablet Oral Stanley Pharmaceuticals, A Division Of Vita Health Products Inc. 1990-12-31 2004-07-26 Canada - Unapproved/Other Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Region Image Bacmin Ferrous fumarate (27 mg/1) + Ascorbic acid (500 mg/1) + Biotin (150 ug/1) + Chromium Cr-51 chloride (0.1 mg/1) + Cupric oxide (3 mg/1) + Cyanocobalamin (50 ug/1) + Flavone (50 mg/1) + Folic acid (1 mg/1) + Magnesium oxide (50 mg/1) + Manganese gluconate (5 mg/1) + Nicotinamide (100 mg/1) + Calcium pantothenate (25 mg/1) + Pyridoxine hydrochloride (25 mg/1) + Riboflavin (20 mg/1) + Selenomethionine (50 ug/1) + Thiamine mononitrate (20 mg/1) + Vitamin A acetate (2000 [iU]/1) + Zinc oxide (22.5 mg/1) + alpha-Tocopherol acetate (30 [iU]/1) Tablet, coated Oral Marnel Pharmaceuticals, Llc 2000-04-01 Not applicable US C-Nate DHA Ferrous fumarate (28 mg/1) + Ascorbic acid (100 mg/1) + Cholecalciferol (400 [iU]/1) + Cupric sulfate pentahydrate (1 mg/1) + Cyanocobalamin (15 ug/1) + Folic acid (1 mg/1) + Magnesium (30 mg/1) + Omega-3 fatty acids (200 mg/1) + Pyridoxine hydrochloride (20 mg/1) + Riboflavin (3 mg/1) + Thiamine mononitrate (3 mg/1) + Vitamin E (30 [iU]/1) + Zinc oxide (20 mg/1) Capsule, gelatin coated Oral Centurion Labs, LLC 2013-01-01 Not applicable US Cavan Folate DHA Ferrous fumarate (65 mg/1) + Ferrous fumarate (65 mg/1) + Ascorbic acid (70 mg/1) + Ascorbic acid (70 mg/1) + Beta carotene (2700 [iU]/1) + Beta carotene (2700 [iU]/1) + Calcium carbonate (100 mg/1) + Calcium carbonate (100 mg/1) + Cholecalciferol (400 [iU]/1) + Cholecalciferol (400 [iU]/1) + Cupric oxide (2 mg/1) + Cupric oxide (2 mg/1) + Cyanocobalamin (12 ug/1) + Cyanocobalamin (12 ug/1) + DL-alpha tocopheryl acetate (30 [iU]/1) + DL-alpha tocopheryl acetate (30 [iU]/1) + Doconexent (250 mg/1) + Doconexent (250 mg/1) + Folic acid (1 mg/1) + Folic acid (1 mg/1) + Magnesium oxide (25 mg/1) + Magnesium oxide (25 mg/1) + Nicotinamide (18 mg/1) + Nicotinamide (18 mg/1) + Pyridoxine hydrochloride (2.5 mg/1) + Pyridoxine hydrochloride (2.5 mg/1) + Riboflavin (1.8 mg/1) + Riboflavin (1.8 mg/1) + Thiamine mononitrate (1.6 mg/1) + Thiamine mononitrate (1.6 mg/1) + Zinc oxide (25 mg/1) + Zinc oxide (25 mg/1) Kit Oral Seton Pharmaceuticals 2010-06-04 2012-03-31 US Cavan Folate DHA Ferrous fumarate (65 mg/1) + Ferrous fumarate (65 mg/1) + Ascorbic acid (70 mg/1) + Ascorbic acid (70 mg/1) + Beta carotene (2700 [iU]/1) + Beta carotene (2700 [iU]/1) + Calcium carbonate (100 mg/1) + Calcium carbonate (100 mg/1) + Cholecalciferol (400 [iU]/1) + Cholecalciferol (400 [iU]/1) + Cupric oxide (2 mg/1) + Cupric oxide (2 mg/1) + Cyanocobalamin (12 ug/1) + Cyanocobalamin (12 ug/1) + DL-alpha tocopheryl acetate (30 [iU]/1) + DL-alpha tocopheryl acetate (30 [iU]/1) + Doconexent (250 mg/1) + Doconexent (250 mg/1) + Folic acid (1 mg/1) + Folic acid (1 mg/1) + Magnesium oxide (25 mg/1) + Magnesium oxide (25 mg/1) + Nicotinamide (18 mg/1) + Nicotinamide (18 mg/1) + Pyridoxine hydrochloride (2.5 mg/1) + Pyridoxine hydrochloride (2.5 mg/1) + Riboflavin (1.8 mg/1) + Riboflavin (1.8 mg/1) + Thiamine mononitrate (1.6 mg/1) + Thiamine mononitrate (1.6 mg/1) + Zinc oxide (25 mg/1) + Zinc oxide (25 mg/1) Kit Oral Seton Pharmaceuticals 2010-06-04 2012-03-31 US Cavan Folate OB Ferrous fumarate (65 mg/1) + Ascorbic acid (70 mg/1) + Beta carotene (2700 [iU]/1) + Calcium carbonate (100 mg/1) + Cholecalciferol (400 [iU]/1) + Cupric oxide (2 mg/1) + Cyanocobalamin (12 ug/1) + DL-alpha tocopheryl acetate (30 [iU]/1) + Folic acid (1 mg/1) + Magnesium oxide (25 mg/1) + Nicotinamide (18 mg/1) + Pyridoxine hydrochloride (2.5 mg/1) + Riboflavin (1.8 mg/1) + Thiamine mononitrate (1.6 mg/1) + Zinc oxide (25 mg/1) Tablet Oral Seton Pharmaceuticals 2010-08-23 2012-05-31 US
Categories
- ATC Codes
- B03AA02 — Ferrous fumarate
- B03AA — Iron bivalent, oral preparations
- B03A — IRON PREPARATIONS
- B03 — ANTIANEMIC PREPARATIONS
- B — BLOOD AND BLOOD FORMING ORGANS
- Drug Categories
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as dicarboxylic acids and derivatives. These are organic compounds containing exactly two carboxylic acid groups.
- Kingdom
- Organic compounds
- Super Class
- Organic acids and derivatives
- Class
- Carboxylic acids and derivatives
- Sub Class
- Dicarboxylic acids and derivatives
- Direct Parent
- Dicarboxylic acids and derivatives
- Alternative Parents
- Unsaturated fatty acids / Carboxylic acid salts / Organic transition metal salts / Carboxylic acids / Organic oxides / Hydrocarbon derivatives / Carbonyl compounds
- Substituents
- Aliphatic acyclic compound / Carbonyl group / Carboxylic acid / Carboxylic acid salt / Dicarboxylic acid or derivatives / Fatty acid / Fatty acyl / Hydrocarbon derivative / Organic oxide / Organic oxygen compound
- Molecular Framework
- Aliphatic acyclic compounds
- External Descriptors
- Not Available
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- R5L488RY0Q
- CAS number
- 141-01-5
- InChI Key
- PMVSDNDAUGGCCE-TYYBGVCCSA-L
- InChI
- InChI=1S/C4H4O4.Fe/c5-3(6)1-2-4(7)8;/h1-2H,(H,5,6)(H,7,8);/q;+2/p-2/b2-1+;
- IUPAC Name
- lambda2-iron(2+) (2E)-but-2-enedioate
- SMILES
- [Fe++].[H]\C(=C(\[H])C([O-])=O)C([O-])=O
References
- General References
- Not Available
- External Links
- PubChem Compound
- 6433164
- ChemSpider
- 10607713
- ChEBI
- 31607
- ChEMBL
- CHEMBL1200640
- Wikipedia
- Iron(II)_fumarate
Clinical Trials
- Clinical Trials Learn More" title="About Clinical Trials" id="clinical-trials-info" class="drug-info-popup" href="javascript:void(0);">
Phase Status Purpose Conditions Count 4 Completed Diagnostic Iron Absorption / Post-gastrointestinal bypass surgery / Roux-en-Y Gastric Bypass 1 4 Completed Treatment Anemia 1 4 Completed Treatment Anemia / Pregnancy, Complications 1 4 Completed Treatment Hyperemesis Gravidarum / Morning Sickness / Nausea / Pregnancy / Vomiting 1 4 Completed Treatment Iron Deficiency (ID) 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
Form Route Strength Bar, chewable Oral Tablet, coated Oral Capsule Cutaneous; Oral Tablet Oral Tablet, film coated Oral Capsule Oral Tablet Oral 65 mg / tab Tablet, film coated Oral 325 mg/1 Kit Oral Tablet, film coated Oral 106 mg/1 Capsule, liquid filled Oral Tablet Oral 300 mg / tab Tablet Oral 200 mg / tab Syrup Oral Capsule, gelatin coated; kit; tablet Oral Kit; tablet Oral Tablet Oral 106 mg/1 Tablet Oral 30 mg / tab Tablet Oral 18 mg / tab Capsule, coated Oral Tablet Oral 6 mg Tablet Oral Capsule, delayed release Oral Tablet, film coated Oral Capsule; kit; tablet Oral Capsule, liquid filled; kit; tablet Oral Capsule, gelatin coated Oral Capsule Oral 100 mg Liquid Oral Tablet, extended release Oral Tablet, sugar coated Oral Tablet, sugar coated Oral Capsule Oral Powder, for solution Oral Tablet Oral 28 mg / tab Tablet, chewable Oral Suspension Oral Powder Oral Tablet Oral 60 mg Tablet Tablet, extended release Oral 18 mg Tablet, sugar coated Oral 200 mg Tablet Oral 200 mg Tablet, coated Oral 200 mg Suspension Oral 76 mg/5mL Solution / drops Oral 375 mg/5ml Tablet, film coated - Prices
- Not Available
- Patents
Patent Number Pediatric Extension Approved Expires (estimated) Region US6667050 No 2003-12-23 2019-04-06 US
Properties
- State
- Not Available
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 13.1 mg/mL ALOGPS logP 0.83 ALOGPS logP -0.041 Chemaxon logS -1.2 ALOGPS pKa (Strongest Acidic) 3.35 Chemaxon Physiological Charge -2 Chemaxon Hydrogen Acceptor Count 4 Chemaxon Hydrogen Donor Count 0 Chemaxon Polar Surface Area 80.26 Å2 Chemaxon Rotatable Bond Count 2 Chemaxon Refractivity 46.28 m3·mol-1 Chemaxon Polarizability 8.65 Å3 Chemaxon Number of Rings 0 Chemaxon Bioavailability 1 Chemaxon Rule of Five Yes Chemaxon Ghose Filter No Chemaxon Veber's Rule No Chemaxon MDDR-like Rule No Chemaxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
- Not Available
- Chromatographic Properties
Collision Cross Sections (CCS)
Not Available
Targets
Build, predict & validate machine-learning models
Use our structured and evidence-based datasets to unlock newinsights and accelerate drug research.
Use our structured and evidence-based datasets to unlock new insights and accelerate drug research.
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- General Function
- Virus receptor activity
- Specific Function
- Cellular uptake of iron occurs via receptor-mediated endocytosis of ligand-occupied transferrin receptor into specialized endosomes. Endosomal acidification leads to iron release. The apotransferri...
- Gene Name
- TFRC
- Uniprot ID
- P02786
- Uniprot Name
- Transferrin receptor protein 1
- Molecular Weight
- 84870.665 Da
References
- Hemadi M, Ha-Duong NT, El Hage Chahine JM: The mechanism of iron release from the transferrin-receptor 1 adduct. J Mol Biol. 2006 May 12;358(4):1125-36. Epub 2006 Mar 13. [Article]
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- General Function
- Peptidyl-proline dioxygenase activity
- Specific Function
- Cellular oxygen sensor that catalyzes, under normoxic conditions, the post-translational formation of 4-hydroxyproline in hypoxia-inducible factor (HIF) alpha proteins. Hydroxylates a specific prol...
- Gene Name
- EGLN1
- Uniprot ID
- Q9GZT9
- Uniprot Name
- Egl nine homolog 1
- Molecular Weight
- 46020.585 Da
References
- Davidson TL, Chen H, Di Toro DM, D'Angelo G, Costa M: Soluble nickel inhibits HIF-prolyl-hydroxylases creating persistent hypoxic signaling in A549 cells. Mol Carcinog. 2006 Jul;45(7):479-89. [Article]
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- General Function
- Transcription factor binding
- Specific Function
- Responsible for the deacetylation of lysine residues on the N-terminal part of the core histones (H2A, H2B, H3 and H4). Histone deacetylation gives a tag for epigenetic repression and plays an impo...
- Gene Name
- HDAC8
- Uniprot ID
- Q9BY41
- Uniprot Name
- Histone deacetylase 8
- Molecular Weight
- 41757.29 Da
References
- Gantt SL, Gattis SG, Fierke CA: Catalytic activity and inhibition of human histone deacetylase 8 is dependent on the identity of the active site metal ion. Biochemistry. 2006 May 16;45(19):6170-8. [Article]
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- General Function
- Acts as a chaperone to prevent the harmful aggregation of alpha-hemoglobin during normal erythroid cell development. Specifically protects free alpha-hemoglobin from precipitation. It is predicted to modulate pathological states of alpha-hemoglobin excess such as beta-thalassemia.
- Specific Function
- Hemoglobin binding
- Gene Name
- AHSP
- Uniprot ID
- Q9NZD4
- Uniprot Name
- Alpha-hemoglobin-stabilizing protein
- Molecular Weight
- 11840.325 Da
References
- Zhou S, Olson JS, Fabian M, Weiss MJ, Gow AJ: Biochemical fates of alpha hemoglobin bound to alpha hemoglobin-stabilizing protein AHSP. J Biol Chem. 2006 Oct 27;281(43):32611-8. Epub 2006 Aug 10. [Article]
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- General Function
- Oxygen transporter activity
- Specific Function
- Involved in oxygen transport from the lung to the various peripheral tissues.
- Gene Name
- HBA1
- Uniprot ID
- P69905
- Uniprot Name
- Hemoglobin subunit alpha
- Molecular Weight
- 15257.405 Da
References
- Zhou S, Olson JS, Fabian M, Weiss MJ, Gow AJ: Biochemical fates of alpha hemoglobin bound to alpha hemoglobin-stabilizing protein AHSP. J Biol Chem. 2006 Oct 27;281(43):32611-8. Epub 2006 Aug 10. [Article]
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- General Function
- Promotes the biosynthesis of heme and assembly and repair of iron-sulfur clusters by delivering Fe(2+) to proteins involved in these pathways. May play a role in the protection against iron-catalyzed oxidative stress through its ability to catalyze the oxidation of Fe(2+) to Fe(3+); the oligomeric form but not the monomeric form has in vitro ferroxidase activity. May be able to store large amounts of iron in the form of a ferrihydrite mineral by oligomerization; however, the physiological relevance is unsure as reports are conflicting and the function has only been shown using heterologous overexpression systems. Modulates the RNA-binding activity of ACO1.
- Specific Function
- 2 iron, 2 sulfur cluster binding
- Gene Name
- FXN
- Uniprot ID
- Q16595
- Uniprot Name
- Frataxin, mitochondrial
- Molecular Weight
- 23134.895 Da
References
- Bencze KZ, Kondapalli KC, Cook JD, McMahon S, Millan-Pacheco C, Pastor N, Stemmler TL: The structure and function of frataxin. Crit Rev Biochem Mol Biol. 2006 Sep-Oct;41(5):269-91. [Article]
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- General Function
- Iron ion binding
- Specific Function
- Stores iron in a soluble, non-toxic, readily available form. Important for iron homeostasis. Has ferroxidase activity. Iron is taken up in the ferrous form and deposited as ferric hydroxides after ...
- Gene Name
- FTH1
- Uniprot ID
- P02794
- Uniprot Name
- Ferritin heavy chain
- Molecular Weight
- 21225.47 Da
References
- Toussaint L, Bertrand L, Hue L, Crichton RR, Declercq JP: High-resolution X-ray structures of human apoferritin H-chain mutants correlated with their activity and metal-binding sites. J Mol Biol. 2007 Jan 12;365(2):440-52. Epub 2006 Oct 7. [Article]
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- General Function
- Structure-specific nuclease with 5'-flap endonuclease and 5'-3' exonuclease activities involved in DNA replication and repair. During DNA replication, cleaves the 5'-overhanging flap structure that is generated by displacement synthesis when DNA polymerase encounters the 5'-end of a downstream Okazaki fragment. It enters the flap from the 5'-end and then tracks to cleave the flap base, leaving a nick for ligation. Also involved in the long patch base excision repair (LP-BER) pathway, by cleaving within the apurinic/apyrimidinic (AP) site-terminated flap. Acts as a genome stabilization factor that prevents flaps from equilibrating into structurs that lead to duplications and deletions. Also possesses 5'-3' exonuclease activity on nicked or gapped double-stranded DNA, and exhibits RNase H activity. Also involved in replication and repair of rDNA and in repairing mitochondrial DNA.
- Specific Function
- 5'-3' exonuclease activity
- Gene Name
- FEN1
- Uniprot ID
- P39748
- Uniprot Name
- Flap endonuclease 1
- Molecular Weight
- 42592.635 Da
References
- Hegde ML, Hegde PM, Holthauzen LM, Hazra TK, Rao KS, Mitra S: Specific Inhibition of NEIL-initiated repair of oxidized base damage in human genome by copper and iron: potential etiological linkage to neurodegenerative diseases. J Biol Chem. 2010 Sep 10;285(37):28812-25. doi: 10.1074/jbc.M110.126664. Epub 2010 Jul 9. [Article]
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- General Function
- Not Available
- Specific Function
- Not Available
- Gene Name
- NEIL1
- Uniprot ID
- Q96FI4
- Uniprot Name
- Endonuclease 8-like 1
- Molecular Weight
- 43683.625 Da
References
- Hegde ML, Hegde PM, Holthauzen LM, Hazra TK, Rao KS, Mitra S: Specific Inhibition of NEIL-initiated repair of oxidized base damage in human genome by copper and iron: potential etiological linkage to neurodegenerative diseases. J Biol Chem. 2010 Sep 10;285(37):28812-25. doi: 10.1074/jbc.M110.126664. Epub 2010 Jul 9. [Article]
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- General Function
- Zinc ion binding
- Specific Function
- Involved in base excision repair of DNA damaged by oxidation or by mutagenic agents. Has DNA glycosylase activity towards 5-hydroxyuracil and other oxidized derivatives of cytosine with a preferenc...
- Gene Name
- NEIL2
- Uniprot ID
- Q969S2
- Uniprot Name
- Endonuclease 8-like 2
- Molecular Weight
- 36826.285 Da
References
- Hegde ML, Hegde PM, Holthauzen LM, Hazra TK, Rao KS, Mitra S: Specific Inhibition of NEIL-initiated repair of oxidized base damage in human genome by copper and iron: potential etiological linkage to neurodegenerative diseases. J Biol Chem. 2010 Sep 10;285(37):28812-25. doi: 10.1074/jbc.M110.126664. Epub 2010 Jul 9. [Article]
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- General Function
- Microtubule binding
- Specific Function
- Repair polymerase that plays a key role in base-excision repair. Has 5'-deoxyribose-5-phosphate lyase (dRP lyase) activity that removes the 5' sugar phosphate and also acts as a DNA polymerase that...
- Gene Name
- POLB
- Uniprot ID
- P06746
- Uniprot Name
- DNA polymerase beta
- Molecular Weight
- 38177.34 Da
References
- Hegde ML, Hegde PM, Holthauzen LM, Hazra TK, Rao KS, Mitra S: Specific Inhibition of NEIL-initiated repair of oxidized base damage in human genome by copper and iron: potential etiological linkage to neurodegenerative diseases. J Biol Chem. 2010 Sep 10;285(37):28812-25. doi: 10.1074/jbc.M110.126664. Epub 2010 Jul 9. [Article]
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- General Function
- Ferroxidase activity
- Specific Function
- Ceruloplasmin is a blue, copper-binding (6-7 atoms per molecule) glycoprotein. It has ferroxidase activity oxidizing Fe(2+) to Fe(3+) without releasing radical oxygen species. It is involved in iro...
- Gene Name
- CP
- Uniprot ID
- P00450
- Uniprot Name
- Ceruloplasmin
- Molecular Weight
- 122204.45 Da
References
- Ha-Duong NT, Eid C, Hemadi M, El Hage Chahine JM: In vitro interaction between ceruloplasmin and human serum transferrin. Biochemistry. 2010 Dec 7;49(48):10261-3. doi: 10.1021/bi1014503. Epub 2010 Nov 9. [Article]
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- General Function
- Transferrin receptor binding
- Specific Function
- Transferrins are iron binding transport proteins which can bind two Fe(3+) ions in association with the binding of an anion, usually bicarbonate. It is responsible for the transport of iron from si...
- Gene Name
- TF
- Uniprot ID
- P02787
- Uniprot Name
- Serotransferrin
- Molecular Weight
- 77063.195 Da
References
- Ha-Duong NT, Eid C, Hemadi M, El Hage Chahine JM: In vitro interaction between ceruloplasmin and human serum transferrin. Biochemistry. 2010 Dec 7;49(48):10261-3. doi: 10.1021/bi1014503. Epub 2010 Nov 9. [Article]
Drug created at July 09, 2018 17:49 / Updated at February 20, 2024 23:54